The National Cancer Institute (NCI) awarded Tigatx Inc., a small business, a $1,418,424 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop a novel monoclonal antibody immunotherapy for EGFR-positive solid cancers. The primary objective is to develop a first-in-class IgA-based antibody treatment called TIGA-001 to target EGFR-mutant non-small cell lung cancer (NSCLC). The funded activities include CMC work, in vitro pharmacology studies, biomarker assay development, and preparations to file an Investigational New Drug (IND) application with the FDA. Demonstrating clinical proof-of-concept with TIGA-001 could open the door to using this therapeutic IgA platform technology to target a wide range of tumor-associated antigens in various cancer settings.
Generated 2/25/25, 5:30 AM